Related Experiment Video

Updated: May 12, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learned

James C Yao1, Diane Reidy Lagunes, Matthew H Kulke

  • 1The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. jyao@mdanderson.org

The Oncologist
|April 26, 2013
PubMed

Insights

Recent advances in neuroendocrine tumor treatment include new drugs and randomized trials. Improving clinical trial design is crucial for developing more effective therapies for neuroendocrine tumors.

Area of Science:

  • Oncology
  • Clinical Trials
  • Pharmacology

Background:

  • The neuroendocrine tumor (NET) field has seen significant progress with four phase III randomized studies completed in the last three years.
  • Two new drugs, everolimus and sunitinib, have been approved for treating well-differentiated pancreatic neuroendocrine tumors.
  • This marks a shift towards evidence-based therapy supported by robust clinical trial data.

Purpose of the Study:

  • To analyze the strengths and weaknesses of recent phase II and III clinical studies in neuroendocrine tumors.
  • To identify limitations in current trial designs that may hinder drug development.
  • To propose improvements in clinical trial design for neuroendocrine tumors.

Main Methods:

  • Review of recent phase II and III randomized controlled trials in neuroendocrine tumors.
  • Analysis of drug development pathways for everolimus and sunitinib.
  • Discussion of common pitfalls in neuroendocrine tumor clinical trial design.

Main Results:

  • Recent trials demonstrate a trend towards randomized controlled studies in neuroendocrine tumors.
  • The development of everolimus and sunitinib highlights both progress and challenges in NET drug approval.
  • Existing trial designs present limitations that can impede the successful development of new NET therapies.

Conclusions:

  • The neuroendocrine tumor research landscape is evolving towards more rigorous clinical trials.
  • Addressing limitations in current trial design is essential for advancing NET therapeutics.
  • Optimizing trial methodologies can accelerate the approval of novel drugs for neuroendocrine tumor patients.
Keywords:
EverolimusNeuroendocrine tumorsOctreotideSunitinibTrial design

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...